The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The role of specific KRAS mutation types in response to treatment by EGFR inhibitors.
O. Fiala
No relevant relationships to disclose
M. Pesek
No relevant relationships to disclose
L. Benesova
No relevant relationships to disclose
B. Belsanova
No relevant relationships to disclose
M. Minarik
No relevant relationships to disclose